September 12, 2019 The pharmaceutical pricing and market access landscape is being transformed by a host of factors. Value-based pricing is making the transition from concept to reality but more clarity is needed on what it means and how it works for different stakeholders. Revolutionary therapies with innovative pricing models are entering the market but at the same time decision-makers at pharma companies are being asked to defend pricing strategies for established products. Meanwhile, much of the US government’s blueprint to lower drug prices is still in the works and yet to be enacted.
The FT Pharma Pricing and Value Summit will explore the future of drug pricing from a balanced perspective. How could the rebate system evolve? Will new powers for Medicare Part D to negotiate drug prices really make a difference to patients? What global factors could change the pricing and market access landscape in the US?
The aim of the Pharma Pricing Summit is to engage with and learn from the full spectrum of pricing and market access stakeholders including pharma companies, insurers, PBMs, employers, providers and patients.
Panel discussions will address the following questions and more:
What impact is President Trump’s Blueprint to Lower Drug Prices having?
What healthcare reforms are being proposed by 2020 presidential candidates and how could they affect drug prices?
How can real-world evidence accelerate market access for advanced therapies?
How can pharma work with other stakeholders to maximize access to gene therapies?
Some of the summit’s key speakers include:
Rick Suarez, Senior Vice President, US Market Access at AstraZeneca
Kathleen Tregoning, Executive Vice President, External Affairs at Sanofi
Jenny Bryant, Senior Vice President, Policy and Research at PhRMA
About the Financial Times
The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.